NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50419-0393-03 | 50419-0393 | LAROTRECTINIB | VITRAKVI | 20.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | OROPHARYNGEAL | Dec 6, 2022 | In Use | |
50742-0340-01 | 50742-0340 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 24, 2022 | In Use | |
50742-0341-01 | 50742-0341 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 24, 2022 | In Use | |
50742-0366-30 | 50742-0366 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 27, 2023 | In Use | |
50742-0416-05 | 50742-0416 | zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Feb 19, 2020 | In Use | ||
50742-0477-01 | 50742-0477 | MELPHALAN HYDROCHLORIDE | MELPHALAN HYDROCHLORIDE | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Feb 18, 2020 | In Use | |||
57894-0505-20 | 57894-0505 | Daratumumab | Darzalex IV | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Oct 15, 2021 | In Use | |
50742-0484-01 | 50742-0484 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use | |
50742-0485-05 | 50742-0485 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 29, 2020 | In Use | |
50742-0492-01 | 50742-0492 | Carmustine | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Jun 25, 2022 | In Use | |||
50742-0495-25 | 50742-0495 | Levoleucovorin | LEVOLEUCOVORIN | 10.0 mg/mL | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | May 8, 2018 | Jun 30, 2021 | In Use |
50742-0496-26 | 50742-0496 | gemcitabine | GEMCITABINE | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 1, 2023 | In Use | |
50742-0521-10 | 50742-0521 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Nov 19, 2021 | In Use | |
50742-0497-53 | 50742-0497 | gemcitabine | GEMCITABINE | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 1, 2023 | In Use | |
50742-0498-05 | 50742-0498 | Gemcitabine | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 1, 2023 | In Use | |
72578-0166-01 | 72578-0166 | Dexamethasone | Dexamethasone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 13, 2024 | In Use | |
50881-0006-03 | 50881-0006 | Retifanlimab-dlwr | ZYNYZ | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Mar 22, 2023 | In Use | |
50881-0013-01 | 50881-0013 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
51013-0190-09 | 51013-0190 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 29, 2018 | In Use | |
51079-0581-01 | 51079-0581 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Feb 26, 1996 | In Use | |
51144-0002-12 | 51144-0002 | Tucatinib | TUKYSA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | Apr 17, 2020 | In Use | |
51407-0181-12 | 51407-0181 | Abiraterone Acetate | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jan 16, 2019 | In Use | |
51407-0748-02 | 51407-0748 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 20, 2023 | In Use | |
51407-0750-10 | 51407-0750 | Cyclophosphamide | CYCLOPHOSPHAMIDE | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 20, 2023 | In Use | |
51407-0760-12 | 51407-0760 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Apr 14, 2023 | In Use |
Found 11120 results — Export these results